Apex Trader Funding (ATF) - News
Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results
Integra LifeSciences (NASDAQ:IART) reported upbeat second-quarter earnings and lowered its FY24 guidance below estimates on Monday.
Integra Lifesciences posted adjusted earnings of 63 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $418.175 million topping expectations of $413.154 million, according to data from Benzinga Pro.
“Our second quarter financial performance continues to reflect the persistent market demand for our diversified portfolio and the commitment of our teams,” said Jan De Witte, Integra LifeSciences’ president and chief executive officer. “Using the learnings from our Boston facility, we are continuing a thorough analysis of our operations and are committed to enhancing the quality, ...